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Abstract: Science and technology – and particularly biotechnology – is 
increasingly central to development agendas in Africa and elsewhere. Implicit 
within the centrality of science and technology lie a set of policy issues 
regarding how best to shape contextually appropriate, innovative and 
sustainable science and technological products in, with and for developing 
countries. The work of the Consultative Group on International Agricultural 
Research (CGIAR) is a case in point and we draw our empirical material from 
the evolution of two biotech bovine vaccine development programmes housed 
in a CG Centre. In the paper, we seek to show that broadening our 
understanding of scientific ‘excellence’ can lead to more innovative, systemic 
research that may produce more appropriate technological solutions. We 
believe this has key implications for science policy, development policy and the 
practice of science for development itself. 
Keywords: science policy; research and development; vaccines; Consultative 
Group on International Agricultural Research; CGIAR; scientific excellence; 
research for development. 
Reference to this paper should be made as follows: Chataway, J., Smith, J.  
and Wield, D. (2007) ‘Shaping scientific excellence in agricultural research’, 
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1 Introduction 
The role of science and technology in development is back on the agenda. High level 
reports make clear that S&T research, particularly biotechnology, has an important 
contribution to make to development – both because it is key to addressing problems in 
health, water supply, energy and food security, and also because it “unlocks the potential 
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of innovation and technology to accelerate economic growth” (Commission for Africa, 
2005). As the Africa Commission report asserts, “specific action for strengthening 
science, engineering and technology capacity is an imperative for Africa” (Commission 
for Africa, 2005). It is also clear that the way in which scientific research is undertaken 
has changed – new technologies and research methods have emerged, new areas of 
interest have arisen, new disciplines have developed. What is less clear is whether 
systems for evaluation of research have adequately evolved alongside the broader 
changes in the field to ensure the level of research excellence – and the type of research 
excellence – that is necessary for development. 
The traditional method of evaluating research excellence has been through peer 
review of journal articles. Peer review publications are an important and probably 
necessary component of evaluation, however using them as primary measures of 
performance may give inappropriate signals to researchers wanting to address complex 
and necessarily interdisciplinary problems of agriculture and poverty. This method gives 
very limited incentive for researchers to respond to the need to promote development 
partnerships and networks and to engage in the messy interdisciplinary work that this 
often entails. Sensitivity to local context and changes in the way research organisations 
are structured may also be relevant. This points to questions of the definition of research 
excellence and how it is measured. More broadly, however, it also underlines questions 
of institutional design, governance, and funding mechanisms. These questions of research 
excellence are taken up in this paper.  
This paper explores the ways in which notions of what is research ‘excellence’ shapes 
knowledge production, technological innovation, development practice and ultimately the 
poverty alleviation agenda. The paper examines recent research and development with 
regard to the development of vaccines for bovine trypanosomiasis and theileriosis 
primarily at the International Livestock Research Institute (ILRI), a member of the 
Consultative Group on International Agricultural Research (CGIAR). The CGIAR is an 
alliance of countries, organisations and foundations that support 15 international 
agricultural centres each with a remit to conduct research on issues relevant to developing 
country agriculture. The CGIAR represents the single largest public goods investment in 
pro-poor international agricultural research in the world and as such plays an important 
role in shaping agricultural ‘research for development’ at a whole range of levels and in 
many different ways.  
The paper maps out differing approaches to the management of bovine 
trypanosomiasis, a protozoa that causes significant livestock and economic losses 
amongst non-indigenous cattle across sub-Saharan Africa. One of these approaches, 
based at the predecessor to ILRI, focused on the production of a vaccine, whilst another 
was a simpler vector management technique. The vaccine approach was characterised by 
a very narrow, institutional focus driven by a science-led agenda. By contrast the vector 
management technique was developed outside of an institution. After work towards the 
creation of a trypanasomiasis vaccine halted in the mid 1990s work continued towards 
the development of a theileroisis vaccine at ILRI. Theileroisis also causes high 
mortalities in breeds nonindigenous to the endemic areas of eastern, central, and parts of 
southern Africa. The organisation and rationale behind this recombinant vaccine 
endeavour was quite different from the trypanosomiasis approach. These case studies 
speak to several important questions about how we conceptualise research ‘excellence’, 
particularly in a developing country context, and how ‘excellence’ does more than label 
science as a successful or failure but also seeks to prescribe how research in conducted, 
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organisationally and conceptually. This analysis will seek to uncover how particular 
conceptualisations of excellence shapes decision-making around funding, donor activities 
and research endeavour, with concrete results for trypanosomiasis and ECF management. 
The paper is split into four sections. The next section sketches a little of the history of  
the CGIAR and in particular ILRI and its predecessors and the forces that have shaped 
policy and research in the institute. Sections 3 and 4 will discuss the institutional histories 
of trypanosomiasis and theileriosis research in East Africa. Section 5 concludes by 
discussing some implications of these case studies for science policy in developing 
countries, institutional organisation and notions of research ‘excellence’. 
2 Institutional context 
The CGIAR system was born in 1971 with the objective of focusing on ‘international 
agricultural research and related activities’, thereby contributing ‘to improved sustainable 
food production in LDC’s such that the nutritional level and general economic well-being 
of their low-income peoples are improved’ (CGIAR 1992 cited in Clark, 1992). The 
CGIAR came to comprise 15 centres located in different parts of the developing world, a 
central secretariat and a Technical Advisory Committee (TAC). An outgrowth of the 
optimism surrounding the Green Revolutions, the CGIAR it was hoped, might produce 
excellent science focusing on central problems and constraints associated with agriculture 
in developing countries (Anderson et al., 1991). 
Autonomous research centres coalesced under the CGIAR umbrella would produce 
excellent applied science to be passed on to national agricultural systems. The CGIAR 
secretariat and the Technical Advisory Committee which serviced all the centres would 
fundraise and offer advice on the direction on work, but would not engage directly in the 
management of individual centres. The belief was that independent centres giving high 
levels of flexibility to teams of scientists were the best vehicle for addressing poverty 
(Baum, 1986). CGIAR centres have had numerous achievements but nothing on the scale 
of the early Green Revolution technologies. It is also now a widely held belief that the 
centres have been much more successful in addressing the problems of middle income 
farmers with access to resources and inputs than meeting the needs of the poorest small 
scale farmers. Driven by a range of different pressures for change the CGIAR system is 
in the throes of change designed to enable it to meet the needs of the poor in the 
developing world. 
The CGIAR’s vision today is undergoing a period of restructuring: 
“The CGIAR system is undergoing redesign to refocus its efforts in a rapidly 
changing world and to make it more effective and visible in the future. This has 
led to a restructuring of the management of the system, a new focus on raising 
external funds from unconventional sources and a new strategy for the future. 
The CGIAR vision is based on a two pronged approach: reducing poverty and 
improving food security.” (CIP, 2004) 
One centre has explicitly aligned itself with the Millennium Development Goals (CIP, 
2004), so that it will judge its own performance in relation to progress towards the 
MDGs. Another centre, the International Rice Research Institute is currently reworking 
its strategy along similar lines. Whilst other centres remain more closely linked to 
research targets, all now see themselves at least in theory as very much part of a complex 
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development project rather than producers of science to be applied by others. Changes  
in external orientation are matched by quite radical shifts in internal organisation of  
the CGIAR system. For instance the CGIAR secretariat and the newly formed  
Science Council, which has replaced the Technical Advisory Council, exercise more 
authority over the Centres and there is much more emphasis on system-wide activities, 
implying collaboration between centres, than there was in the past. This reflects the 
perceived need for much more networking and partnership based activity. There is now  
a widely held belief that whilst science and technology remain key to alleviating  
rural poverty, responding to the needs of the poorest, requires intense collaborative and 
interdisciplinary work. 
The journey from applied laboratory based research centres to integrated development 
actors has been at times fraught and is certainly not complete. Replete with contradictions 
and difficulties the work and focus of the CGIAR centres remains controversial and 
increasingly difficult to conceptualise. One of the pivotal areas of current debate is about 
how the work of the centres should be evaluated. How is work judged to be excellent or 
otherwise? In order to understand the debate it is important to go back and consider a 
little more of the CGIAR history. In this paper, we briefly explore that history focusing 
on vaccines work at ILRI.  
3 The institutional evolution of ILRI 
ILRI was officially formed in 1994, following the ‘disestablishment’ of two other 
CGIAR centres – the International Laboratory for Research on Animal Diseases 
(ILRAD) and the International Livestock Centre for Africa (ILCA). In 1973, ILRAD  
had resulted from a Memorandum of Agreement was signed between the Government  
of Kenya and the Rockefeller Foundation (acting on behalf of the CGIAR) for the 
establishment of ILRAD, as an international and autonomous, non-profit organisation. 
According to this agreement: 
“(t)he purpose of the Laboratory will be to serve as a world centre for research 
on ways and means of conquering, as quickly as possible, major animal 
diseases which seriously limit livestock industries in Africa and in many  
other parts of the world. The Laboratory will concentrate initially on intensive 
research concerning the immunological and related aspects of controlling 
trypanosomiasis and theileriosis (mainly East Coast Fever). It may, however, 
eventually extend its research to other serious animal disease problems for 
which its facilities and expertise are appropriate…In carrying forward its 
program, the Laboratory will develop close linkages with governmental and 
regional organisations undertaking research on the same or related disease 
problems.” (ILRAD, 1973) 
ILRAD was, therefore, set up as a laboratory-based scientific research institute with a 
global mandate to develop immunological solutions (mainly vaccines) to theileriosis and 
trypanosomiasis. In practice, as a result of the distribution and effects of the diseases, 
ILRAD would focus on Africa. The explicit focus on immunological solutions; vaccines, 
and latterly particularly sub-unit vaccines, represented a conscious institutional decision 
to focus attention on one possible solution rather than other potential solutions such as 
vector entrapment, or spraying and dipping using acaracides in the case of East Coast 
fever and trypanocides in the case of typanosomiasis (Homewood et al., 2006). There 
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were, and remain, issues, deficiencies and negative impacts with all alternative solutions 
but it is clear from interviews with ex-ILRI staff that an immunological solution would be 
the scientifically most ‘elegant’ solution.  
ILRAD initially focused on developing a sound epidemiological and immunological 
understanding of the two diseases. Early achievements in trypanosomiasis-related 
research included in vitro propagation of one of the main trypanosome species of interest, 
and the discovery of a limited number of metacyclic antigens in this species. In the field 
of theileriosis, investigations of immune responses to Theileria infection had taken place, 
along with the development of techniques to culture T. parva strains. By the early 1980s, 
a vaccine against East Coast Fever (ECF) was expected within the next five years. An 
‘immunological solution’ against trypanosomosis, however, was proving elusive – the 
complexity of antigenic variation amongst trypanosomes was becoming increasingly 
apparent (ILRAD, 1982).  
The first systemic review of ILRAD recognised this initial work as fundamental but 
called for a reorganisation into ‘projects’ that would encourage horizontal integration and 
a more multidisciplinary approach. Consequently, following the 1980 review Theileriosis 
research was divided into three project areas. The first built on established East Coast 
Fever epidemiology research, specifically disease control through the ‘infection and 
treatment’-method of immunisation. The other two theileriosis projects focused on 
developing vaccines based on antigens from Theileria sporozoites (form of parasite 
transmitted from infected ticks to cattle) on the one hand, and Theileria schizonts (form 
of parasite that develops in the cells of infected cattle) on the other (ILRAD, 1983).  
Trypanosomosis research was also divided into three project areas. Again, the first 
focused on epidemiology. One component of this project concentrated on the 
identification and characterisation of trypanosomes, which fed into vaccine development. 
Another component included the collaborative project with ILCA and the International 
Centre for Insect Physiology and Ecology (ICIPE) on the productivity of trypanotolerant 
livestock – the Trypanotolerance Network. The second trypanosomosis project 
investigated methods to control the parasites, and the third at improving the immune 
responses of infected animals. Each project area was further divided into several  
‘sub-projects’ (ILRAD, 1983). These initial attempts at organisational restructuring were 
a move away from the clearly linear ‘Mode 1’ characterisation of ILRAD’s early years. 
As these projects became more complex and involve more stakeholders, evaluating them 
on the basis of purely ‘excellent’ science became increasingly inadequate. 
4 Trypanosomiasis research and development 
Trypanosomiasis is caused by unicellular protozoan parasites, termed trypanosomes, 
which propagate in the blood and tissue fluids of their hosts. Pathogenic species of 
Trypanosoma occur in many parts of the developing world and infect amongst others, 
humans, livestock and water buffalo. The susceptibility of host species differs – the 
disease can be either acute or chronic. Trypanosomiasis is frequently fatal in highly 
susceptible animals (such as ‘Zebu’ cattle and some exotic breeds), while in more 
resistant ones the disease results in decreased productivity. Symptoms of trypanosomiasis 
include sporadic periods of fever, wasting, enlargement of lymph nodes, anaemia, 
infertility and immune dysfunction, and tsetse flies are the main vectors.  
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Trypanosomes assume different morphologies during their lifecycles in hosts and 
vectors (tsetse flies). Once in the bloodstream, the trypanosomes begin to divide, and 
trigger an immune response from the host – antibodies are produced against the ‘antigen 
face’ of the parasites. The trypanosomes have developed a survival strategy to avoid 
destruction by the host immune system. Trypanosome infection occurs as successive 
waves of parasites (known as parasitaemic waves) appearing in the blood and tissue 
spaces of the host. The host mounts an immune response to the repertoire of antigens 
present in each wave. By the time this immune response has occurred, some 
trypanosomes have altered their ‘antigenic faces’ and these will initiate the next wave of 
trypanosome infection, for which the host immune system is not prepared.  
For decades, trypanosomiasis control has been attempted mainly through two routes  
– vector (tsetse fly) control and trypanocide drugs. The former has involved a range of 
approaches, from tsetse habitat clearings and the use of impregnated traps, to the 
widespread application of insecticides and the use of the sterile male technique. Indeed in 
the early to mid 1980s according to one authoritative source ‘the days of tsetse seemed 
numbered’ (Torr et al., 2005). Large scale spraying at ground and aerial levels had all but 
eliminated tsetse from large areas of east, west and southern parts of Africa that had 
previously been infested. These and other promising vector control methods began to  
fail, however, due to changing research policy positions, donor funding priorities, and 
increasing pest resistance. 
This was the context in which ILRAD embarked on a biological solution to the 
trypanosomiasis problem in the early 1980s, namely the discovery of a vaccine. But as 
outlined above the development of such a vaccine was hampered due to antigenic 
variation and vaccine research efforts effectively ended at ILRI approximately five years 
ago. The focus of trypanosomiasis research at ILRI has since shifted to the genetic 
characterisation of trypanotolerant cattle. 
5 Theileriosis vaccine development 
Theileriosis refers to a complex of diseases caused by protozoan parasites from the genus 
Theileria. These parasites invade and propagate in the cells of the immune and 
haematopoietic (blood cell producing) systems of their hosts, mainly cattle. As in the case 
of trypanosomiasis, susceptibility to the disease differs amongst breeds – in highly 
susceptible, imported and more productive breeds, the disease is acute and frequently 
fatal (within three to four weeks of infection). Even in more resistant breeds, lower 
productivity follows recovery from an infection. Hence theileriosis is a real development 
problem. In East and Central Africa the most important species is Theileria parva, which 
is transmitted by tick, and which causes East Coast Fever (ECF) in cattle. The parasite is 
closely related to the causative agent of malaria in humans.  
Similar to trypanosomes, the T. parva parasite exists in different morphological states 
during the course of infection. Control of theileriosis has relied on the application of 
acaracides, chemical agents, against ticks. In high-risk areas, cattle have been sprayed 
with, or dipped in, acaracides on a frequent basis. However, this is expensive, and tick 
populations have been shown to develop resistance to available chemicals. Pasture 
management has also proved to be effective, but small-scale livestock keepers often lack 
the resources required to implement this. The most widely used approach remains the 
‘Infection and Treatment Method’ (ITM) of immunisation, described below. 
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The prospects of a vaccine against theileriosis were initially encouraged with the 
discovery that an episode of theileriosis in an animal led to immunity. Subsequently, 
however, distinct strains of T. parva were found, and it was established that broad 
protection could only follow exposure to a variety of strains. This obstacle was overcome 
when it was discovered that exposure to a combination of three different strains appeared 
to provide a broad immunity, and when it became possible to harvest sporozoite forms of 
the parasite from ticks. This became the basis of the live vaccine used in ITM. Different 
strains of sporozoites extracted from infected ticks were injected into animals, and  
the animals were simultaneously treated with long-acting tetracycline antibiotics. While 
preventing full-blown clinical manifestations, the immunised animals occasionally show 
mild and transient symptoms of the disease. ITM, although widely implemented, has 
several shortcomings. It requires a cold chain facility to maintain viable sporozoites, 
antibiotics, and expertise to monitor animals after treatment. These factors contribute to 
the high costs of ITM. Furthermore, immunised animals become carriers of the parasite, 
and can potentially infect ticks and spread theileriosis. ILRAD initially, and ILRI 
subsequently, have been involved in the quality control aspects of ITM stocks. 
With regard to theileriosis, vaccine research remains ongoing, however. Certainly to 
an extent this is due to the fact that prospects for a vaccine against East Coast Fever are 
rather better than for trypanosomiasis, even despite the discovery of numerous strains of 
T. parva. Current vaccine research is organised in a very different manner than that of the 
trypanosomiasis vaccine efforts. The UK Department for International Development 
(DFID) are the primary funders of the research and due to their shifting funding priorities 
and prevailing donor thinking regarding the support of problem-oriented research they 
have played an important role in reorganising the way vaccine research is taking place at 
ILRI. It is certainly quite different and considerably more systematic than the original 
trypanosomiasis research at ILRAD. 
DFID chose to fund the research from the position that the regional economy of  
East Africa loses about £300 million a year due to the disease (according to ILRI). 
Framing research funding from this perspective forces a shift towards a more systemic, 
problem-oriented mode of research that is built around the fact that the steps needed to 
make the vaccine work (and this means looking at the entire value chain, down to 
dissemination and appropriate costing) are as important as the continuing lab work. 
DFID, initially, did not view East Coast fever as a priority for intervention (Perry et al., 
2002) but nevertheless ILRI successfully built an argument for support of their research 
efforts. The proof of this was in the funding. The project, then, was funded on 
assessments of the likely impact of the vaccine on the economy and on livelihoods, the 
basis of the advanced state of ILRI’s existing research and therefore the likelihood of a 
workable vaccine being developed, and the support of a system that would allow the 
vaccine to be effectively disseminated and widely used. The science was firmly framed 
within social and developmental contexts. 
The project is housed at ILRI, but the systemic approach demanded by DFID means 
that a network of partners (not just lab partners) are essential to the success of the 
venture. The project is conceived of as a needs-based public-private partnership, ensuring 
all the components necessary to develop and disseminate the vaccine are in place in good 
time. A complex set of partnerships between the public and private sectors across two 
continents has played an important role in moving the science forward. Private sector 
ventures (the French biotech firm Merial) are involved in producing the vaccine for trial 
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and will be responsible for the delivery of the vaccine in a context where there is little 
demand, because of a lack of resources, and to pull the vaccine vials to where they are 
needed the most. Kenya’s National Agricultural Research System plays a role in vaccine 
trials and monitoring, and further collaborators are based at universities worldwide.  
There is a high degree of complementarity between the major partners. ILRI has 
conducted much of the essential immunological research. Kenya’s state national 
agricultural research system is responsible for trialling the vaccine and monitoring 
impacts of cattle. Merial, a French biotechnology company, produce the vaccine. The 
modality of the project itself is shifting thinking about partnerships, about research, and 
about what constitutes excellence. 
6 Implications for science policy: rethinking excellence 
The ILRAD/ILRI experience clearly shows that something more systematic than 
excellent laboratory-based research was needed in producing concrete technologies to 
manage and control trypanosomiasis. Research ‘excellence’ reached a point where it 
became clear that the development of a vaccine was not going to prove possible despite 
15 years of concerted effort. The tsetse fly continues to be a scourge but, as we have  
said, there are other methods of dealing with trypanosomiasis in cattle, for example the 
use of traps and targets and bush clearing. Much of the research for this had produced 
good quality science throughout Africa but ILRAD did not ever really engage with it  
as a ‘research trajectory’. Several key players we interviewed underlined this as a  
‘missed opportunity’ that had potentially delayed more effective vector management of 
trypanosomiasis by decades. Within ILRI itself science continues to play a role but  
in the more limited sense of diagnostic research and genetic characterisation of 
trypanotolerance in cattle. Of course the question still remains as to why these other 
research trajectories were not given more emphasis in the early days since despite the fact 
that ILRAD established itself as a centre of bovine immunology, arguably it could still 
have been proactive in other senses. ILRAD at that time, despite being a member of the 
CGIAR, had absolute authority to shape its own research agenda and we argue that it 
took a very narrow, institutional view of research excellence – it was conceived as an 
‘island of excellence’ with little external engagement except with collaborating 
laboratories. This focus on excellence as science endeavour meant ILRAD did not seek  
to support a systemic approach that might have identified and supported other 
approaches. ILRAD’s ability to broadly shape its own remit and research agenda led to a 
narrow conceptualisation of excellence. A tighter institutional focus on its own research 
agenda may have led to a more inclusive interpretation of excellence and consequently 
more engagement. 
The case of East Coast fever is rather more complex. The ILRI developed ITM 
‘cocktail’ was finally approved for limited use in Kenya in Maasai cattle in the last  
two years. This is the culmination of many years of research within ILRI/ILRAD and 
other East African research institutes. Other countries, particularly in Zambia with 
Belgian support, have continued to conduct live vaccine research, testing and production. 
In the intervening period live vaccines have been produced and used in Southern  
Africa. Vaccination has been adopted only slowly in Kenya (and this may have been  
due to vested interests on the part of either veterinary authorities and/or acaracide 
manufacturers). In fact it has been suggested that one reason for the recent relaxation of 
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prohibition in Kenya is the increasing problem of acaracide resistance in the tick 
population. Arguably this has made the need for alternative solutions much more 
pressing. A final argument concerns the high costs involved in production and delivery, 
though these seem nowadays to be smaller than they once were. 
In fact ILRAD, in its initial mandate, made the strategic (and somewhat isolated) 
decision to look for an immunological solution to the East Coast fever problem. From 
that point on the organisation saw itself as a high quality centre for research in bovine 
immunology with the ultimate objective of discovering vaccines for both cattle diseases 
through molecular research into the biology of the problem. ITM research continued but 
gradually gave way to the alternative approach and currently it plays almost no part in 
ILRI activity. Hence it is apparent that there were (and still are) three prime mechanisms 
for dealing with the disease. In practice ILRAD took the view that the molecular East 
Coast fever vaccine should be the preferred route. This may have been in part due to 
problems associated with the complexity and the expense associated with the ITM 
method. At the time of the early decision in the 1980s it seems reasonable to suggest that 
existing organisations would have had trouble actually testing and delivering this crude 
vaccine no matter how successful it had been in early trials.1 Conversely the prospects for 
a science-based vaccine must have seemed promising at the time and there was clearly 
excitement about being involved in such cutting-edge science. 
However, the issue no longer seems so clear cut. The biology of theileriosis is now 
recognised as much more complex than initially expected and donors funding this 
research are inevitably wondering whether the expense will ever pay off in practical 
terms for the resource-poor farmer, no matter how good the research is in purely 
scientific terms.2 There is some evidence (interview data) that the fallback remedy of 
cattle dipping is becoming less effective due to growing acaricide resistance in the ticks. 
In addition it may very well be that capacity now exists for ITM delivery because of 
institutional learning, improved infrastructure, donor support and possible private  
sector investment.  
ILRI research is inevitably more embedded in a highly complex set of stakeholder 
interests than ILRAD ever had been. In the early days of the 1980s the organisation took 
the view that its major role was one of placing the bulk of its resources firmly behind the 
search for molecular vaccines. In a sense this became the central thrust, one that fitted 
well into a CGIAR ethos that focused on the great importance of strategic science and 
regional excellence in solving the world’s food problems although why alternative 
scientific approaches were not given greater consideration at that time raises interesting 
questions of scientific management and political economy. Also though other stakeholder 
interests were present these appear to have played little or no role in such a specifically 
defined and science-led strategy. But as we have outlined the wider context has changed 
in several important ways. Nowadays, mainly as donor priorities have shifted, it is 
probably no longer possible for ILRI to function in an exclusively science-led modality. 
This leaves it in a position where it must rethink its research organisation.  
One way of looking at this history is that it represents the shift of an institution 
operating according to Mode 1 principles to one operating on the basis of a Mode 2 
agenda, which are explained later in the paper. 
But the implications of the case are many. Reframing excellence in not a simple, 
notional process that equates to the binaries of ‘Mode 1’ and ‘Mode 2’. Rather it occurs 
at the confluence of some of the most important and problematic issues of institutional 
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research and development and how it should be organised, how institutions internalise 
change, and how institutions engage within broader networks. It is a political, value-laden 
process. These values extend to other issues: if excellence is to be re-thought, how do we 
assess it? How do we define and audit something that by its design is meant to be fluid, 
innovative and systemic? Clearly there ought to be a move beyond just peer-review  
as a measure of success and progress, but what should it be? One of the issues of the 
DFID-funded theileriosis project has been how to assess progress. What the scientists 
view as progress and what DFID consider progress are not always the same, and simple 
peer-review does little to help. 
There are more positive, less problematic implications. The process of broadly 
defining excellence is part of a process of understanding the need, and the reality, of a 
more systematic system of innovation perspective to shaping science and technology. 
There are many examples of the benefits of a system of innovation approach (Chataway, 
2005; Hall, 2005) but one concern, raised above, has been how to operationalise 
something that by its own definition should be organic, complex and responsive. Perhaps 
new understandings of what ‘excellence’ is and how to promote it can lead to a more 
systemic, embedded science and technology in the context of developing countries? The 
final section reflects on some of the more theoretical dimensions of these questions. 
7 Research excellence in context 
Accounts of Mode 1/Mode 2 knowledge production literature describe a shift towards  
a process of knowledge production that is problem-oriented, multidisciplinary, 
contextualised and undertaken by teams of specialists from different fields and 
backgrounds (Gibbons et al., 1994; 2003). This implies a change in the meaning of 
excellence, to incorporate objectives such as focused problem-solving. It also implies a 
change to the assessment of excellence, since the peer-review system may no longer be 
the dominant form of assessment; at a minimum it may require incorporation of measures 
of impact that consider output in terms of social outcomes and not only in terms of the 
production of applied research. 
The innovation systems literature suggests that new challenges of S&T research can 
best be met by undertaking research within ‘innovation networks’. These networks are 
defined by a web of collaborative relationships between organisations and their research 
partners, government and private funders as well as industry. Within this framework 
knowledge is produced as a result of applied research but also as a product of interaction 
between agencies. Again this implies a shift in the way research excellence is perceived 
since assessment must be concerned not only with evaluation of applied research (by peer 
review) but also with evaluation of the processes of institutional change that facilitate the 
production of the second type of (institutional) knowledge.  
The importance of factors of institutional design is also identified in the discussion  
of the experience of interdisciplinary research (Scottish Higher Education Funding 
Council, 1997). This experience places emphasis on institutional design, not only in 
terms of physical location and organisational structure but also in terms of control 
pathways and resource allocation mechanisms. These elements are important because of 
their effect on the incentive structure of individuals, and also their influence on 
facilitating organisational change. 
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The concept of governance shifts the emphasis from institutions as physical structures 
to institutions as systems of norms and procedures. The emphasis here is on the 
importance of management structures, incorporating stakeholders, and systems of 
accountability for an organisation’s capacity to produce excellent research. The 
implication for the assessment excellence from the discussion of both interdisciplinarity 
and governance is attention to institutional processes over and above institutional output 
(Shcolte, 2002).  
Drawn together, the theoretical discussions potentially lead to two major conclusions 
for research excellence. First, research excellence may incorporate a broad set of 
objectives including scientific excellence but also social and economic impacts, the 
development of collaborative relationships and participative forms, good governance, 
effectiveness and cost efficiency. The second potential conclusion is that the expansion of 
outlook in terms of objectives will also require a corresponding expansion of outlook in 
terms of assessment, including output measures of research produced and the outcomes 
of this research, as well as analysis of institutional processes.  
In response to the question of what constitutes research excellence, a manager of 
donor funds in this area stated: “In my opinion research that has an impact on the lives of 
people in developing countries is more excellent than excellent but is not usually 
described in terms of excellence”. While this statement seems confusing at first, in fact it 
captures two important points relating to research excellence. First, talking about research 
excellence often involves people talking across each other – not only do people use 
different terminology to discuss excellence, they also mean different things when they 
use the term. Second, the statement effectively illustrates the difficulty of trying to bring 
together questions of relevance and scientific excellence in evaluation of research.  
The considerable difficulties of managing the tensions between different perspectives of 
excellence, of engaging in a dialogue on excellence that is substantive rather than just 
becoming part of development discourse, and of operationalising evaluation systems, 
should not be glossed over. Despite these difficulties the question of research excellence 
warrants serious consideration because of its profound importance. It is important, as a 
director of a major donor agency pointed out, for guaranteeing the credibility of research 
but also for achieving clarity on what is meant by research excellence and how it can be 
achieved is also key to ensuring that development aid for S&T research is managed in a 
consistent way and is as effective as possible. 
An initial concern with the way S&T research is traditionally undertaken, and  
the corresponding definition of research excellence, is that it may not be sensitive to 
context and the need to promote development. Traditionally S&T research institutions 
have been organised around single scientific disciplines. Research under this approach is 
decided by a small group of scientists and aimed at disciplinary excellence and therefore 
may ‘not give attention to whether an R&D institution has and properly articulates  
a sustainable development purpose’. In addition to the fact that such institutions are  
often treated as isolated entities rather than as parts of broader knowledge networks or 
innovation systems, this means that they are not responsive to specific social and 
economic problems and general national policy. As Dr. John Mugabe, Head of Science 
and Technology at NEPAD, articulates, development of such institutions has been  
very much ‘supply-driven’, with resources directed to infrastructure and training which 
‘left behind organisational entities that are not capable of responding to domestic and 
international demands’ (Mugabe, 2003).  
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This underlines the question of whether current definitions of research excellence are 
even appropriate to developing countries. As Chataway et al. (2005) emphasise: 
“Although institutions in industrially developed countries put much effort into 
judging and reviewing research performance, and can therefore legitimately 
claim excellence, it is not clear that institutions in developing countries benefit 
from using the same criteria.” 
While it will always be necessary to have evaluation systems in place to ensure rational 
allocation of funding, it is important that innovation is not constrained by a particular 
understanding of what excellence might, or ought, to be. 
Besides the need to promote development discussed above, there may be other 
objectives of S&T research in a development context that are not incorporated into 
definitions of research excellence such as international recognition and peer review. 
Ability to resolve specific development problems and generate appropriate technology 
towards sustainable development is, for example, an area that is largely neglected under 
this definition. Other concerns that are central to undertaking research in development 
S&T and therefore might also form part of a broader set of criteria, are cost effectiveness, 
community outreach, and capacity building. 
Furthermore, there is a question of whether a measure of scientific productivity as the 
number of peer-reviewed journal articles provides the right incentives to scientists 
involved in development research. It is unfortunate for researchers in organisations in 
both developing and developed countries that current peer review mechanisms and 
research assessment exercises do not provide rewards for contributions made to 
development. As Maureen O’Neil, president of the International Development Research 
Centre (IDRC) underlines: 
“Too often IDRC hears stories, especially from younger faculty, that they get 
little or no credit towards career promotion and tenure for the research they do 
on IDRC and CIDA-funded projects. This is considered ‘research for 
development’ or research that is worthy but not ‘excellent’.” (O’Neil, 2003) 
The problems outlined above indicate the importance of re-considering research 
excellence – in itself and also in relation to development objectives. A final consideration 
is how research excellence relates to broader changes in the way science and technology 
research is undertaken. It may be necessary for the theory and policy design of research 
excellence to evolve in relation to new practice: 
“Now is the time to consider how we define ‘excellence’ and ‘innovation’ and 
how we will measure research results against them. By ‘excellence’, we may 
mean ‘urgently needed and challenging research’ – that which is problem 
oriented, multi-disciplinary (preferably comparative) and carried out by teams 
networking internationally across research sites and policy jurisdictions. By 
‘innovative’, we may value co-production of knowledge through innovations 
only made possible by bringing together the experience of experts in Canada 
and other countries and applying that knowledge to solve real problems.” 
(O’Neil, 2003) 
It is clear to go beyond rethinking new forms of excellence to promoting and practicing 
new forms of excellence will require major shifts in the organisational and institutional 
architecture of R&D in developing country contexts. We are under no illusion as to the 
difficulty of affecting changes of this nature. The institutional history of livestock  
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research in East Africa and trypanosomiasis and East Coast fever research and 
development in particular presents a compelling case for both rethinking and reworking 
‘excellence’, however. 
8 Conclusion 
It is our view that scientific research is clearly of fundamental importance in dealing  
with a variety of livestock diseases that continue to plague the poor farmer in this part of 
the world. And therefore it is also clear that research institutes like ILRI should continue 
to play a pivotal role in technology development particularly where the necessary 
interventions are science-based. It is also clear the CGIAR as a whole will continue to 
play a major role in defining and driving research for agricultural development.  
We believe that more recent developments in ILRAD/ILRI’s history such as the 
merger, the failure to develop a trypanosomiasis vaccine, and shifts in donor priorities  
– one result of which is the DFID-funded theileriosis project, are incrementally 
broadening how ‘excellence’ is conceived. If excellence is conceived purely in terms of 
scientific research ILRAD had some initial successes in terms of widening our 
knowledge, if excellence is conceived from a developmental perspective (also part of its 
original remit) it could be argued it has failed in terms of providing solutions. Embedding 
the institution within a broader context and a broader set of stakeholders and networks 
inevitably leads to differing perspectives of what research ‘excellence’ ought to be.  
There are of course contestations between stakeholders and actors in view of what they 
may view excellence to be and managing this plurality will be one of the most important 
tasks facing ILRI and R&D institutions worldwide. Excellence has a political dimension 
as well.  
We believe that this contestation can lead to the shaping of a broader,  
more-development focused and context-bound conceptualisation of what R&D 
‘excellence’ ought to be in developing country contexts and this can in turn lead to  
better science policy and practice. Policy that understands the importance of systemic 
approaches, appropriate prioritisation of research, resources and activities, and 
demonstrates a more nuanced understanding of the contexts of need and of capacity 
which institutions, and research, operate. In this way science and technological practice 
can make its fullest contribution to development. 
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Notes 
1 At the time of setting up ILRAD, the countries of the region looked to it for the next 
generation of vaccines and, as molecular techniques for parasite characterisation were 
developed, they offered tools with which ITM strains could be better defined and compared. 
The cost of isolating, defining and producing national strains made it difficult for countries to 
adopt control measure and most national programmes have been sustained through donor 
support – UK in Kenya, FAO and the Netherlands in Tanzania now and Denmark in the past, 
and Belgium in Zambia. 
2 Although there is evidence that the project is building other kinds of research and innovative 
capacity, cf. Smith (2005). 
    
 
 
   
   
 
   
   
 
   
       
 
